Immune Thrombocytopenic Purpura Clinical Trial
Official title:
Efficacy of Helicobacter Pylori Eradication for the 1st Line Treatment of Immune Thrombocytopenic Purpura (ITP) Patients With Moderate Thrombocytopenia
We designed a study for evaluate the efficacy of Helicobacter pylori eradication for the 1st
line treatment of immune thrombocytopenic purpura (ITP) patients with moderate
thrombocytopenia.
If this eradication treatment is revealed effective on ITP patients with more than 30X109/L
of platelet, it would be valuable treatment especially for young ITP patients with mild to
moderate thrombocytopenia.
lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days. (Jeil Pharm. CO. LTD. will provide lansoprazole.) C13-UBT, at 4 weeks after onset of treatment, to determine eradication ;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02077192 -
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
| Completed |
NCT01621204 -
A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
|
Phase 3 | |
| Completed |
NCT01719692 -
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
|
N/A | |
| Completed |
NCT01730352 -
Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT01713855 -
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
|
N/A | |
| Not yet recruiting |
NCT05093257 -
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
|
||
| Completed |
NCT01390649 -
A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)
|
Phase 4 | |
| Completed |
NCT01672151 -
Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia
|
N/A | |
| Completed |
NCT01439321 -
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
|
N/A | |
| Completed |
NCT00774202 -
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
|
Phase 2/Phase 3 | |
| Completed |
NCT02273960 -
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05585944 -
" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "
|
N/A | |
| Recruiting |
NCT03177629 -
H. Pylori Eradication for Moderate ITP
|
Phase 3 | |
| Not yet recruiting |
NCT05835050 -
Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital
|
N/A | |
| Active, not recruiting |
NCT03395210 -
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
|
Phase 2 | |
| Completed |
NCT00621894 -
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
|
Phase 2 | |
| Not yet recruiting |
NCT06444477 -
Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
|
||
| Completed |
NCT01652599 -
Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT
|
Phase 2 | |
| Completed |
NCT00426270 -
Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
|
Phase 3 | |
| Completed |
NCT02085993 -
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training
|
N/A |